At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed prostate adenocarcinoma, clinical stage T1b–T2c
- ✓Pretreatment PSA ≤20 ng/mL
- ✓Gleason score ≤7
- ✓Suitable erectile function (IIEF Q1 score ≥2)
- ✕Prior pelvic radiotherapy
- ✕Prior or planned radical prostatectomy
- ✕Other active malignancy within 5 years (except nonmetastatic skin cancer or early-stage CLL)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Outcomes Following Intensity Modulated Radiation Therapy With And Without Erectile Tissue Dose Sparing For Favorable To Intermediate Risk Prostate Cancer
In Brief
A clinical study evaluating radiation therapy for Prostate Cancer and 2 related conditions. Completed, enrolled 116 participants across 1 site.
Detailed Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Intensity-modulated radiation therapy (radiation directed at the tumor more precisely than in standard radiation therapy) may reduce damage to healthy tissue near the tumor. It is not yet known whether reducing the dose of radiation to erectile tissue will help prevent erectile dysfunction. PURPOSE: This randomized phase III trial is studying intensity-modulated radiation therapy alone to see how well it works compared to intensity-modulated radiation therapy with reduced doses to erectile tissue in treating patients with stage II prostate cancer.
Study Details
Timeline
Interventions
Patients undergo conventional intensity-modulated radiotherapy (IMRT) once daily 5 days a week for approximately 7.5 weeks.